Careers  |  Sign In  |  Register  |   Twitter

Evidence Based Initiation of Therapy of Diabetes

Best Practice Series in Diabetes - Type 2

Zachary Bloomgarden, MD, Editor of The Journal of Diabetes and Clinical Professor in the Dept. of Medicine at the Mount Sinai School of Medicine, reviews an evidence-based approach to the treatment of diabetes.

Disclosures:
Speaker’s Bureau: Merck, NovoNordisk, GSK
Advisory Panel: Merck, BMS, Astra Zeneca, Boehringer Ingelheim, Biodel
Consultant: Merck, Novartis, Dainippon Sumitomo Pharma America, Forest Laboratories
Stock/Shareholder: Covidien, Bard, Novartis, Roche, Stryker